Suppression of the TUFT1/AKT pathway in HCC cells using either TUFT1 shRNA or the AKT phosphorylation inhibitor (MK2206) abrogated the promoting effects of BRD9 on cell growth, metastasis, and EMT. Here, TUFT1 is linked to hepatocellular carcinoma.